AFT Pharmaceuticals Limited

ASX:AFP ISIN:NZAFTE0001S4

AFT Pharmaceuticals LimitedAFT Pharmaceuticals Limited (ASX:AFP) (NSX:AFT) is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs5. Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to outlicense our products to local licensees and distributors to over 125 countries around the world.

 
    

News

AFT Pharmaceuticals Limited (ASX:AFP) Sees Strong FY 26 as Revenue Reaches New Record

🕔5/22/2025 10:34:31 AM 511

AFT Pharmaceuticals Limited (NSX:AFT) (ASX:AFP) today reports it has again achieved another year of record revenue with annual sales exceeding $200 million1 and it is now firmly focused on its revenue target of $300 million by the end of the 2027 financial year.

Read Full Article
###

128 COMPANY PROFILE VIEWS

  • This Page Viewed: (Since Published: 126) 

Company Data

    Headquarters
  • Level 1, Neilson Building, 129 Hurstmere Road
    Auckland
    New Zealand
  • Telephone
  • +64 9 488 0232 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.aftpharm.com

More News Results

  • 2025/05/22: FY2025 Distribution Notice correction*
  • 2025/05/22: FY2025 Distribution notice*
  • 2025/05/22: FY2025 Presentation*
  • 2025/05/22: FY2025 Annual Report*
  • 2025/05/22: FY2025 Market Release*
  • 2025/05/22: FY2025 App2*
  • 2025/05/01: AFTto announce full year results on Thursday May 22 2025*
  • 2025/03/31: March investor update*
  • 2025/03/26: ASX small cap presentation 250326*
  • 2025/01/13: NEW YEAR LETTER TO INVESTORS*
*refer to company website

Social Media